MoonLake Immunotherapeutics (MLTX)
| Market Cap | 3.04B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -145.21M |
| Shares Out | 63.47M |
| EPS (ttm) | -2.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 425,800 |
| Open | 46.67 |
| Previous Close | 46.61 |
| Day's Range | 46.32 - 48.02 |
| 52-Week Range | 31.42 - 58.26 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 73.33 (+53.22%) |
| Earnings Date | Aug 6, 2025 |
About MLTX
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MLTX stock is "Strong Buy." The 12-month stock price target is $73.33, which is an increase of 53.22% from the latest price.
News
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is...
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody ® sonelokimab across...
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company foc...
MoonLake Immunotherapeutics: A Buy At Dips
MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed r...
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today...
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflamma...
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon
MoonLake Immunotherapeutics is set to release results from both the phase 3 VELA-1 and VELA-2 studies using sonelokimab to target moderate-to-severe Hidradenitis Suppurativa patients in mid-2025. The ...
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulos...
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stag...
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 20...
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data. Despite a competitive landscape with established IL-17 inhibitors, Moon...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program...
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company focused on nanobody development with its drug Sonelokimab. Sonelokimab has shown positive results in clinical trials for psoriasis, hid...
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing t...
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for H...
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody ® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology C...